CRISPR Therapeutics AGCRSPNASDAQ
Loading
Year-over-year operating income growth rate
Percentile
P36
Within normal range
vs 3Y Ago
-0.6x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -17.19% |
| Q3 2025 | 42.41% |
| Q2 2025 | -54.51% |
| Q1 2025 | -129.80% |
| Q4 2024 | 41.35% |
| Q3 2024 | 27.19% |
| Q2 2024 | -7.59% |
| Q1 2024 | -302.04% |
| Q4 2023 | 152.55% |
| Q3 2023 | -39.05% |
| Q2 2023 | -47.66% |
| Q1 2023 | 50.98% |
| Q4 2022 | 27.88% |
| Q3 2022 | 0.48% |
| Q2 2022 | -4.14% |
| Q1 2022 | -20.78% |
| Q4 2021 | -13.08% |
| Q3 2021 | -116.90% |
| Q2 2021 | 765.79% |
| Q1 2021 | -6.29% |
| Q4 2020 | -16.63% |
| Q3 2020 | -14.51% |
| Q2 2020 | -9.65% |
| Q1 2020 | -770.00% |
| Q4 2019 | -92.11% |
| Q3 2019 | 353.10% |
| Q2 2019 | -13.55% |
| Q1 2019 | -7.06% |
| Q4 2018 | 8.50% |
| Q3 2018 | -32.58% |
| Q2 2018 | -38.11% |
| Q1 2018 | -2877.47% |
| Q4 2017 | 104.12% |
| Q3 2017 | -10.63% |
| Q2 2017 | -2.71% |
| Q1 2017 | 18.04% |
| Q4 2016 | -73.24% |
| Q3 2016 | 11.76% |
| Q2 2016 | -42.10% |
| Q1 2016 | 4.22% |